Drug Target Review – Issue #2 2016
16 June 2016 | By Drug Target Review
Included in this issue: Mass Spectrometry, Rare Diseases, Omics, Kinases, Stem Cells, Label-Free and much more...
List view / Grid view
Articles
Omics In-Depth Focus 2016
Featured in this Omics In-depth Focus: The next revolution in stratified medicine-molecular phenotyping with metabolomics; Pharmacometabolomics as the key to personalised medicine...
Stem Cells In-Depth Focus 2016
Featured in this Stem Cells In-depth Focus: Translating stem cell biology into drug discovery; Mechanism-informed phenotypic screening – the missing link for cancer drug discovery; Analysis of human stem cell interactions at the single-cell resolution...
Organs-on-chips gearing up to disrupt the microbiome market
The human microbiome, comprising of the complex and dynamic microbial communities found on the human body, is essential to our health and observed differences in its composition between patients and healthy people have lead to speculations about the involvement of bacteria in disease development. Such differences have provided evidence towards…
Advanced techniques and applications of LC-MS in small molecule drug discovery
A key process in drug discovery is the ability to identify new drug candidates by screening chemical libraries of small molecules, natural products or extracts against a biological target and selecting lead compounds with desirable therapeutic effects. Medicinal chemistry has the challenging role of not only ensuring that the chemical…
Rare Diseases Q&A
Releasing colourful balloons into the air to symbolise people who are affected by rare diseases was one of the many ways in which this year’s Rare Disease Day was marked in February. The once-yearly, global campaign aims to raise awareness among the general public and decision-makers about these illnesses and…
Inhibition of RNA-containing viruses by artificial RNases
The toxicity and antiviral properties of 24 low-molecular-weight artificial RNases (artRNases) including peptides, peptidomimetics, N-alkyl-substituted 1,4-diazabicyclo[2.2.2]octane (DABCO) and a silver (I) complex with cystine were analysed for viruses containing single-stranded and double-stranded genomic RNA (the tick-borne encephalitis virus; TBEV and the influenza virus, respectively) in vitro and in vivo by…
New horizons in next-generation small molecule kinase inhibitors
In the pre-imatinib (Glivec®) era, two out of three patients died within five years from chronic myeloid leukemia and there was no hope for a curative treatment. Imatinib’s introduction in 2001 marked a breakthrough – as the first approved kinase inhibitor, it was a game-changer in cancer therapy and revolutionised…
Under the microscope with Joseph Jammal, Chief Operating Officer of Cisbio Bioassays
16 June 2016 | By Drug Target Review
Drug Target Review talks to Joseph Jammal, Chief Operating Officer of Cisbio Bioassays, to find out more about assay developments and future innovations in this area of drug discovery...
Pharmacometabolomics as the key to personalised medicine
Blanketed administration of drugs to all populations assumes that all patients respond similarly. Despite pharmaceutical companies’ efforts to develop drugs with large therapeutic windows, there are often and inevitably subpopulations of individuals who will either not respond to therapy or will respond with adverse effects...
Mechanism-informed phenotypic screening – the missing link for cancer drug discovery?
Cancer cells exhibit huge phenotypic diversity, with many well-defined phenotypes, such as invasion, deregulated proliferation and immune evasion, contributing to disease outcomes, making them uniquely amenable to phenotypic screening1...
Leaving EU could be a setback for Life Sciences in the UK
8 June 2016 | By Dr Alexander Moscho, Bayer UK & Ireland CEO
In this opinion piece, Dr Alexander Moscho, Bayer UK & Ireland CEO, says a vote to leave the EU will deter investment and make it harder for patients to access new medicines...
JLINX: a first of its kind European incubation model to catalyse scientific innovation
31 May 2016 | By Kurt Hertogs, PhD, Head of JLINX, Johnson & Johnson Innovation
Kurt Hertogs discusses JLINX - a new initiative that aims to catalyse scientific innovation...
PIM/FLT3 dual inhibition
13 May 2016 | By Wojciech Czardybon, PhD, Project Manager, Discovery Laboratory Manager, Selvita S.A.
In this article, Wojciech Czardybon of Selvita discusses the potential of PIM/FLT3 dual inhibition in treating acute myeloid leukaemia and other cancers...
Soligenix on IDR technology and SGX942
10 May 2016 | By Victoria White, Digital Content Producer
We discuss Innate Defense Regulator (IDR) technology with Soligenix's Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942...